Literature DB >> 8229681

Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis.

J R Wade1, A W Kelman, C A Howie, B Whiting.   

Abstract

A prospective simulation study has been carried out to evaluate the effect of potential misspecification of the absorption rate constant (ka) in population pharmacokinetic analysis when few to no concentration-time data were available in the absorption phase and estimation of ka was not possible. Data were simulated for 100 subjects using a one-compartment model at steady state with first-order input. Data were generated over a range of ka values: ka was misspecified in the NONMEM analysis by factors of 0.25, 0.5, 1, 2, 3, and 4. In general, clearance (CL) was typically estimated with a small, constant underprediction, regardless of the range of misspecification of ka or whether data were present in the absorption phase. The same was not true for volume of distribution (V), values were biased and sensitive to the degree of misspecification, but only when the data contained even a little information about absorption. If studies are to be designed in which information absorption is either not required or is of no therapeutic use, then blood samples could be concentrated in the postabsorption phase and the absorption input fixed according to the best a priori information available.

Mesh:

Year:  1993        PMID: 8229681     DOI: 10.1007/bf01059771

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  10 in total

1.  An evaluation of population pharmacokinetics in therapeutic trials. Part III. Prospective data collection versus retrospective data assembly.

Authors:  E J Antal; T H Grasela; R B Smith
Journal:  Clin Pharmacol Ther       Date:  1989-11       Impact factor: 6.875

2.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Pharmacokinetics of quinidine in male patients. A population analysis.

Authors:  C N Verme; T M Ludden; W A Clementi; S C Harris
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

4.  The population pharmacokinetics of theophylline in neonates and young infants.

Authors:  E S Moore; R G Faix; R C Banagale; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1989-02

5.  An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies.

Authors:  T H Grasela; E J Antal; R J Townsend; R B Smith
Journal:  Clin Pharmacol Ther       Date:  1986-06       Impact factor: 6.875

6.  Pharmacokinetics of the digoxin-quinidine interaction via mixed-effect modelling.

Authors:  P J Williams; J Lane; W Murray; M A Mergener; M Kamigaki
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

7.  Population pharmacokinetics of lithium.

Authors:  D M Jermain; M L Crismon; E S Martin
Journal:  Clin Pharm       Date:  1991-05

8.  Postinduction carbamazepine clearance in an adult psychiatric population.

Authors:  E S Martin; M L Crismon; P J Godley
Journal:  Pharmacotherapy       Date:  1991       Impact factor: 4.705

9.  Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trials.

Authors:  N M Graves; T M Ludden; G B Holmes; R H Fuerst; I E Leppik
Journal:  Pharmacotherapy       Date:  1989       Impact factor: 4.705

10.  Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates.

Authors:  L Collart; T F Blaschke; F Boucher; C G Prober
Journal:  Dev Pharmacol Ther       Date:  1992
  10 in total
  28 in total

1.  Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.

Authors:  Alessandro Schipani; Marco Siccardi; Antonio D'Avolio; Lorena Baietto; Marco Simiele; Stefano Bonora; Sonia Rodríguez Novoa; Lorena Cuenca; Vincent Soriano; Nitipatana Chierakul; Natpratou Saguenwong; Charoen Chuchuttaworn; Janelle M Hoskins; Anne M Dvorak; Howard L McLeod; Gerry Davies; Saye Khoo; David J Back; Giovanni Di Perri; Andrew Owen
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Population pharmacokinetic analysis of simvastatin and its active metabolite with the characterization of atypical complex absorption kinetics.

Authors:  Seok-Joon Jin; Kyun-Seop Bae; Sang-Heon Cho; Jin-Ah Jung; Unjib Kim; Sangmin Choe; Jong-Lyul Ghim; Yook-Hwan Noh; Hyun-Jung Park; Hee-Sun Kim; Hyeong-Seok Lim
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

3.  Pharmacokinetics of ribavirin in patients with hepatitis C virus.

Authors:  Janet R Wade; Eric Snoeck; Frank Duff; Matthew Lamb; Karin Jorga
Journal:  Br J Clin Pharmacol       Date:  2006-12       Impact factor: 4.335

4.  The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach.

Authors:  Lena E Friberg; Geoffrey K Isbister; L Peter Hackett; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

5.  Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model.

Authors:  P Jacqmin; E Snoeck; E A van Schaick; R Gieschke; P Pillai; J-L Steimer; P Girard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-19       Impact factor: 2.745

6.  Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.

Authors:  Radojka M Savic; Daniël M Jonker; Thomas Kerbusch; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-26       Impact factor: 2.745

7.  Use of prior information to stabilize a population data analysis.

Authors:  Per O Gisleskog; Mats O Karlsson; Stuart L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-12       Impact factor: 2.745

8.  Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients.

Authors:  Zheng Jiao; Xiao-jin Shi; Zhong-dong Li; Ming-kang Zhong
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

9.  Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.

Authors:  Milly E de Jonge; Alwin Dr Huitema; Jan Hm Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

10.  Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.

Authors:  Stéphane Corvaisier; Bruno Charpiat; Cyril Mounier; Martine Wallon; Gilles Leboucher; Mounzer Al Kurdi; Jean-François Chaulet; François Peyron
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.